Peptinnovate announces change of name to Immune Regulation, strengthening of the Board and successful fundraise

Peptinnovate announces change of name to Immune Regulation, strengthening of the Board and successful fundraise

Peptinnovate Ltd (‘Peptinnovate’ or the ‘Company’, a biotechnology company developing novel immune modulators for immunological and inflammatory diseases, announces that it has changed its corporate name from Peptinnovate to Immune Regulation with immediate effect. The new website for Immune Regulation is www.immuneregulation.com.

Richard Nagle, CEO of Immune Regulation, formerly Peptinnovate, commented:
“Re-branding the Company as Immune Regulation better reflects our expanding clinical pipeline of novel immuno-modulating therapies following Peptinnovate’s acquisition of Immune Regulation Ltd. and its lead molecule, IRL201805 earlier this year.

“IRL201805 is currently in clinical development for rheumatoid arthritis. Along with our other lead drug candidate PIN201104, currently in clinical development for asthma and dermatological indications, we now have two therapeutic development programmes that have successfully completed early stage clinical studies. We are continuing to execute on our vision to develop these first in class immune-modulators in a broad range of immunological and inflammatory diseases.”

Menu